Evarista Osime Odaburhine, Ezimokhai Tijani Paul, Airiagbonbu Blessing
Department of Medical Laboratory Science, School of Basic Medical Sciences, College of Medical Sciences, University of Benin, Benin City, Nigeria.
Indian J Sex Transm Dis AIDS. 2020 Jan-Jun;41(1):83-87. doi: 10.4103/ijstd.IJSTD_107_17. Epub 2020 Jun 18.
BACKGROUND: In many developing countries with a significant proportion of human immunodeficiency virus (HIV)-positive patients are women of child-bearing age and would require antiretroviral therapy. This study aimed at evaluating the effect of highly active antiretroviral therapy (HAART) on some specific clotting profile in HIV-positive pregnant women. SUBJECTS AND METHODS: This study comprised 150 patients consisting of 50 blood samples from pregnant women on HAART as test subjects, 50 pregnant HIV-positive women that were not on HAART as test subjects, and 50 pregnant HIV-negative women which served as controls. The test subjects were attending the prevention of mother-to-child transmission Clinic at the Central Hospital, Benin City. Specific clotting factors assayed were factors 11, V, V11, V111, 1X, X, X1, and X11. All were done using ELISA methods. RESULTS: Factors 11 and V were reduced significantly in HIV-infected pregnant women on HAART and those not on HAART ( < 0.05) when compared with HIV-negative pregnant women. A significant increase in factors V11, V111, 1X, X, and X11 were observed in HIV-positive patients on HAART and those not on HAART when compared with HIV-negative pregnant women ( < 0.05). However, when HIV-positive patients on HAART were compared to HIV-positive women not on HAART, no statistical difference were observed ( > 0.005). CONCLUSION: There are changes in clotting profile of HIV-positive women on HAART and on those not on HAART and these changes are not due to the administration of antiretroviral therapy.
背景：在许多发展中国家，相当一部分人类免疫缺陷病毒（HIV）阳性患者是育龄妇女，她们需要抗逆转录病毒疗法。本研究旨在评估高效抗逆转录病毒疗法（HAART）对HIV阳性孕妇某些特定凝血指标的影响。 对象与方法：本研究包括150名患者，其中50名接受HAART的孕妇血液样本作为测试对象，50名未接受HAART的HIV阳性孕妇作为测试对象，50名HIV阴性孕妇作为对照。测试对象均在贝宁城中心医院的母婴传播预防诊所就诊。检测的特定凝血因子为因子Ⅺ、Ⅴ、Ⅶ、Ⅷ、Ⅸ、Ⅹ、Ⅺ和Ⅻ。所有检测均采用酶联免疫吸附测定（ELISA）方法。 结果：与HIV阴性孕妇相比，接受HAART和未接受HAART的HIV感染孕妇的因子Ⅺ和Ⅴ显著降低（P<0.05）。与HIV阴性孕妇相比，接受HAART和未接受HAART的HIV阳性患者的因子Ⅶ、Ⅷ、Ⅸ、Ⅹ和Ⅺ显著升高（P<0.05）。然而，将接受HAART的HIV阳性患者与未接受HAART的HIV阳性女性进行比较时，未观察到统计学差异（P>0.005）。 结论：接受HAART和未接受HAART的HIV阳性女性的凝血指标均有变化，且这些变化并非由抗逆转录病毒疗法引起。
Inflamm Res. 2018-10-1
Cell Mol Biol (Noisy-le-grand). 2003-12
Med Wieku Rozwoj. 2003
Trop Med Int Health. 2010-5-18
Br J Anaesth. 2015-12
S Afr Med J. 2012-3-2
J Antimicrob Chemother. 2010-12-5
Cochrane Database Syst Rev. 2010-3-17
Best Pract Res Clin Obstet Gynaecol. 2010-1-22
S Afr J Surg. 2009-5
Zotero 插件